Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resource Use in Swedish Nursing Homes: A Repeated Cross-Sectional Follow-Up Study.

International journal of geriatric psychiatry·2026
Same author

[Health economic aspects of dementia].

Lakartidningen·2026
Same author

Health-economic challenges for new Alzheimer's disease treatments.

The journal of prevention of Alzheimer's disease·2026
Same author

A Student-Run Health Initiative Inspired by a Hospital's Commitment to Community Partnership.

Journal of primary care & community health·2026
Same author

Prevention of dementia using mobile phone applications (PRODEMOS) - a health-economic cost-utility analysis in people aged 55-75 years with low socio-economic status.

The journal of prevention of Alzheimer's disease·2026
Same author

Impact of an exercise and nutrition program on caregiver time with residents in institutional care-A secondary analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: May 13, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

7.9K

IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease.

Ron Handels1, William L Herring2, Farzam Kamgar3

  • 1Alzheimer Centre Limburg, Faculty of Health Medicine and Life Sciences, School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|October 9, 2024
PubMed
Summary

Health economic models for Alzheimer's disease (AD) treatments show varied predictions due to different data implementations. Standardized reporting and long-term data are recommended to improve accuracy for mild cognitive impairment (MCI) due to AD.

Keywords:
Alzheimer’s diseasecross-validationdecision-analytic modelinghealth-economic evaluation

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.8K
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.1K

Related Experiment Videos

Last Updated: May 13, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

7.9K
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.8K
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.1K

Area of Science:

  • Health economics
  • Biostatistics
  • Neuroscience

Background:

  • Decision-analytic models for Alzheimer's disease (AD) treatments face challenges with limited short-term trial data and uncertainty in long-term outcome extrapolation.
  • This study addresses the need for transparency and credibility in modeling methods for emerging AD therapies.

Purpose of the Study:

  • To cross-compare Alzheimer's disease (AD) decision models in a hypothetical scenario of disease-modifying treatment for mild cognitive impairment (MCI) due to AD.
  • To identify and discuss variations in model predictions and their underlying assumptions.

Main Methods:

  • A benchmark scenario in the US was established for MCI due to AD.
  • Nine modeling groups generated predictions using hypothetical trial efficacy estimates over a 10-year horizon.
  • Model predictions were assessed based on various outcome measures and analysis methods, excluding treatment costs.

Main Results:

  • Significant variation was observed in model predictions for time in MCI, quality-adjusted life-year gains, and incremental costs.
  • Differences in implementing treatment effectiveness, including choice of outcome measure and analysis method, led to prediction variability.
  • Predicted mean time in MCI ranged from 2.6 to 5.2 years for controls and 0.1 to 1.0 years for intervention differences.

Conclusions:

  • The implementation of trial data in health-economic models significantly impacts predictions for Alzheimer's disease (AD) treatments.
  • Recommendations include addressing outcome measure choices in sensitivity analyses and standardizing prediction reporting.
  • Utilizing registries for long-term disease progression data is crucial to reduce uncertainty in future AD treatment modeling.